Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

被引：224

作者：

Kerr, K. M. ^{[1
,2
]}

Bubendorf, L. ^{[3
]}

Edelman, M. J. ^{[4
]}

Marchetti, A. ^{[5
]}

Mok, T. ^{[6
]}

Novello, S. ^{[7
]}

O'Byrne, K. ^{[8
,9
]}

Stahel, R. ^{[10
]}

Peters, S. ^{[11
]}

Felip, E. ^{[12
]}

机构：

[1] Aberdeen Royal Infirm, Dept Pathol, Aberdeen, Scotland

[2] Aberdeen Univ Med Sch, Aberdeen, Scotland

[3] Univ Basel Hosp, Inst Pathol, CH-4031 Basel, Switzerland

[4] Univ New Mexico Canc Ctr, Albuquerque, NM USA

[5] Univ Fdn, Ctr Predict Mol Med, Ctr Excellence Ageing, Chieti, Italy

[6] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China

[7] Univ Turin, Azienda Osped Univ San Luigi Orbassano, Dept Oncol, Thorac Oncol Unit, I-10124 Turin, Italy

[8] Trinity Coll Dublin, Dublin, Ireland

[9] Queensland Univ Technol, Brisbane, Qld 4001, Australia

[10] Univ Zurich Hosp, Clin Oncol, CH-8091 Zurich, Switzerland

[11] CHU Vaudois, Dept Oncol, Lausanne, Switzerland

[12] Vall dHebron Univ Hosp, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2014年 / 25卷 / 09期

关键词：

ESMO; consensus; non-small-cell lung cancer; pathology; molecular testing; recommendations; MESSENGER-RNA EXPRESSION; IN-SITU HYBRIDIZATION; EXTERNAL QUALITY ASSESSMENT; FACTOR RECEPTOR MUTATIONS; ALK GENE REARRANGEMENTS; EML4-ALK FUSION GENE; PHASE-III TRIAL; BRONCHIAL BIOPSY; INTERNATIONAL-ASSOCIATION; HISTOLOGICAL CLASSIFICATION;

D O I：

10.1093/annonc/mdu145

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas.

引用

页码：1681 / 1690

页数：10

共 96 条

[1]

[Anonymous], J CLIN ONCOL S

[2]

[Anonymous], 2004, Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs

[3] Effect of prolonged formalin fixation on the immunohistochemical reactivity of breast markers [J].

Arber, DA .

APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2002, 10 (02) :183-186

[4] The impact of pre-analytical processing on staining quality for H&E, dual hapten, dual color in situ hybridization and fluorescent in situ hybridization assays [J].

Babic, Andrea ;

Loftin, Isabell R. ;

Stanislaw, Stacey ;

Wang, Maria ;

Miller, Rachel ;

Warren, Stephanie M. ;

Mang, Wenjun ;

Lau, Alexandria ;

Miller, Melanie ;

Wu, Ping ;

Padilla, Mary ;

Grogan, Thomas M. ;

Pestic-Dragovich, Lidija ;

McElhinny, Abigail S. .

METHODS, 2010, 52 (04) :287-300

[5] Randomized International Phase III Trial of ERCC1 and RRM1 Expression-Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non-Small-Cell Lung Cancer [J].

Bepler, Gerold ;

Williams, Charles ;

Schell, Michael J. ;

Chen, Wei ;

Zheng, Zhong ;

Simon, George ;

Gadgeel, Shirish ;

Zhao, Xiuhua ;

Schreiber, Fred ;

Brahmer, Julie ;

Chiappori, Alberto ;

Tanvetyanon, Tawee ;

Pinder-Schenck, Mary ;

Gray, Jhanelle ;

Haura, Eric ;

Antonia, Scott ;

Fischer, Juergen R. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (19) :2404-+

[6] ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers [J].

Bergethon, Kristin ;

Shaw, Alice T. ;

Ou, Sai-Hong Ignatius ;

Katayama, Ryohei ;

Lovly, Christine M. ;

McDonald, Nerina T. ;

Massion, Pierre P. ;

Siwak-Tapp, Christina ;

Gonzalez, Adriana ;

Fang, Rong ;

Mark, Eugene J. ;

Batten, Julie M. ;

Chen, Haiquan ;

Wilner, Keith D. ;

Kwak, Eunice L. ;

Clark, Jeffrey W. ;

Carbone, David P. ;

Ji, Hongbin ;

Engelman, Jeffrey A. ;

Mino-Kenudson, Mari ;

Pao, William ;

Iafrate, A. John .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) :863-870

[7] p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma [J].

Bishop, Justin A. ;

Teruya-Feldstein, Julie ;

Westra, William H. ;

Pelosi, Giuseppe ;

Travis, William D. ;

Rekhtman, Natasha .

MODERN PATHOLOGY, 2012, 25 (03) :405-415

[8] Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients [J].

Boukovinas, Ioannis ;

Papadaki, Chara ;

Mendez, Pedro ;

Taron, Miquel ;

Mavroudis, Dimitris ;

Koutsopoulos, Anastasios ;

Sanchez-Ronco, Maria ;

Javier Sanchez, Jose ;

Trypaki, Maria ;

Staphopoulos, Eustathios ;

Georgoulias, Vassilis ;

Rosell, Rafael ;

Souglakos, John .

PLOS ONE, 2008, 3 (11)

[9] Observer variability in histopathological reporting of non-small cell lung carcinoma on bronchial biopsy specimens [J].

Burnett, RA ;

Howatson, SR ;

Lang, S ;

Lee, FD ;

Lessells, AM ;

McLaren, KM ;

Nairn, ER ;

Ogston, S ;

Robertson, AJ ;

Simpson, JG ;

Smith, GD ;

Tavadia, HB ;

Walker, F .

JOURNAL OF CLINICAL PATHOLOGY, 1996, 49 (02) :130-133

[10] BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma [J].

Busacca, Sara ;

Sheaff, Michael ;

Arthur, Kenneth ;

Gray, Steven G. ;

O'Byrne, Kenneth J. ;

Richard, Derek J. ;

Soltermann, Alex ;

Opitz, Isabelle ;

Pass, Harvey ;

Harkin, D. Paul ;

Quinn, Jennifer E. ;

Fennell, Dean A. .

JOURNAL OF PATHOLOGY, 2012, 227 (02) :200-208

← 1 2 3 4 5 6 7 8 9 10 →